Showing results (291-300 of 335) with videos related to
Sort By:
Pageof 34
Cancer Discovery|March 24, 2017
Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid TumorsDejan Juric, Ian Krop, Ramesh K Ramanathan, et al.Investigational New Drugs|October 12, 2012
A phase 1 study of TRC102, an inhibitor of base excision repair, and pemetrexed in patients with advanced solid tumorsMichael S Gordon, Lee S Rosen, David Mendelson, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 4, 2005
Phase I pharmacokinetic-pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancersRamesh K Ramanathan, Donald L Trump, Julie L Eiseman, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 19, 2011
Phase 1 study of the safety, tolerability, and pharmacokinetics of TH-302, a hypoxia-activated prodrug, in patients with advanced solid malignanciesGlen J Weiss, Jeffrey R Infante, E Gabriela Chiorean, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 7, 2004
Phase I and pharmacologic study of intermittently administered 9-nitrocamptothecin in patients with advanced solid tumorsWilliam C Zamboni, Laura L Jung, Merrill J Egorin, et al.BMC Medical Genomics|June 20, 2014
Whole genome sequencing reveals potential targets for therapy in patients with refractory KRAS mutated metastatic colorectal cancerVijayalakshmi Shanmugam, Ramesh K Ramanathan, Nicole A Lavender, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2019
Phase IB/II Randomized Study of FOLFIRINOX Plus Pegylated Recombinant Human Hyaluronidase Versus FOLFIRINOX Alone in Patients With Metastatic Pancreatic Adenocarcinoma: SWOG S1313Ramesh K Ramanathan, Shannon L McDonough, Philip A Philip, et al.Journal of Gastrointestinal Oncology|January 5, 2018
A phase 2 trial of personalized cytotoxic therapy based on tumor immunohistochemistry in previously treated metastatic pancreatic cancer patientsRamesh K Ramanathan, Glen J Weiss, Richard G Posner, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 5, 2011
Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trialDaniel D Von Hoff, Ramesh K Ramanathan, Mitesh J Borad, et al.JAMA Oncology|October 4, 2019
Response Rate Following Albumin-Bound Paclitaxel Plus Gemcitabine Plus Cisplatin Treatment Among Patients With Advanced Pancreatic Cancer: A Phase 1b/2 Pilot Clinical TrialGayle S Jameson, Erkut Borazanci, Hani M Babiker, et al.Pageof 34